ИСТИНА |
Войти в систему Регистрация |
|
ФНКЦ РР |
||
Objective: CATIE Trial. (Keefe RS, 2007) found no differences between typical and atypical antipsychotics in their impact on cognitive functioning, but practitioners consider atypical antipsychotics safer for cognition of patients. We planned to assess the impact of the type of antipsychotic treatment on cognitive functioning of stable patients with schizophrenia and residual psychotic symptoms. Methods: patients of both sex, aged from 18 to 65 with clinical diagnosis Schizophrenia (DSM///) with residual psychotic symptoms in remission (no psychotic episode for at least 3 months before screening) would be tested with Brief Assessment of Cognition in Schizophrenia (BACS) and Continuous Performance Test (CPT)/ Positive and Negative Symptome Scale (PANSS) Results 77 patients aged (age 38, 1 SD 13.9, male ///) were included into the study. The patients were divided into two groups in accordance with the type of antipsychotic treatment. The results are presented in the table1. No difference in total PANSS score or scored PANSS subscales were found. Conclusion. In our study the patients in remission with schizophrenia and residual psychotic symptoms stabilized on atypical antipsychotics demonstrated better cognitive functioning, especially in working and verbal memory and processing. This benefit is important in terms of general adaptation.